Kawasaki disease is a major cause of acquired coronary disease in children, and timely treatment with immunoglobulin and aspirin significantly reduces cardiac complications.
Answers are grounded in this paper and cite their sources.
Supports immunoglobulin and aspirin to reduce cardiac complications in Kawasaki disease; leaves open need for prospective UK trials before practice change.
Kawasaki disease (KD) is an acute self-limiting systemic vasculitis of unknown etiology and the most common cause of acquired coronary disease in children aged 6 months to 5 years. The inflammatory process results in coronary arteritis, aneurysmal lesions, arterial thrombotic occlusion or even sudden death. The diagnostic tests are unknown but treatment with immunoglobulin and aspirin is effective at reducing cardiac complications from 25 to 4.7% in the UK. Myocardial, endocardial or pericardial inflammation may occur acutely or many years later and abnormalities of myocardial blood flow may require ongoing medication, interventional catheterization or even cardiac surgery. There are several new drugs that may have important roles to play in managing KD in children and young adults.
No takes yet. Share an insight, caveat, or question.
Wood et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: